Allovir
Latest round
- Series B
Last raised
- May 2019
Total raised
- $121M
Investors
- 8
About Allovir
Allovir, Inc.Founded in 2013 and headquartered in Cambridge, US, Allovir, Inc. develops therapies for viral infections.25 mn.Allovir, Inc. specializes in innovative treatments targeting viral infections, particularly those affecting immunocompromised patients. Their primary products leverage proprietary cellular technology aimed at improving patient outcomes.In their most recent financial year, Allovir, Inc.Allovir, Inc.25 mn, to support the development and marketing of their therapies. The company is focusing on expanding its product offerings and entering new markets. Specific expansion targets and launch dates for upcoming products are part of their strategic roadmap as they seek to broaden their reach beyond the US.
Who invested in Allovir
8 investors across 1 round
See all investors in Allovir
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
May 8, 2019
Amount
$121M
Investors
Questions about Allovir
Who invested in Allovir?
Allovir has 8 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Allovir raised?
Allovir has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Allovir last raise money?
Allovir's most recent round on record is a Series B, in May 2019.
What does Allovir do?
Allovir is a biotechnology company.
Where is Allovir headquartered?
Allovir is headquartered in Cambridge, US.
Which VCs invest in companies like Allovir?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Allovir's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Allovir? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.